According to Dr. Michael Weber, many patients will often present at the physician’s office with previously undiagnosed or unrecognized risk factors, which occurs frequently with high blood pressure, lipid disorders, and diabetes. Consequently, initial therapeutic strategies must be aggressive to properly control those who are truly at high risk. However, according to the panelists, not all patients are the same, not all patients are diagnosed at the same time, and there are countless variables that may impact the trajectory of a disease state. Therefore, it is vital to emphasize and drive personalized medicine with individualized goals. While there are contentions among different patient populations regarding the merits of pharmacotherapy and lifestyle modifications, the panelists believe that a comprehensive and balanced strategy is what will garner the most beneficial outcomes.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More